Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAT2A | P31153 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22880747 | 1.00 | APP (0.67) | APPKCNH2TSHRLMNATP53 | |
| SCHEMBL9999674 | 0.93 | APP (0.59) | APPKCNH2TSHRLMNATP53 | |
| SCHEMBL10270322 | 0.88 | APP (0.53) | APPKCNH2TSHRLMNATP53 | |
| SCHEMBL9678907 | 0.87 | APP (0.77) | APPKCNH2TSHRMAT2A | |
| SCHEMBL900823 | 0.87 | APP (0.77) | APPKCNH2TSHRMAT2A | |
| SCHEMBL9680312 | 0.87 | APP (0.77) | APPKCNH2TSHRMAT2A | |
| SCHEMBL19003408 | 0.87 | APP (0.77) | APPKCNH2TSHRMAT2A | |
| SCHEMBL15138717 | 0.82 | TSHR (0.50) | APPKCNH2TSHRLMNATP53 | |
| SCHEMBL7527708 | 0.81 | CYP3A4 (0.65) | APPTSHRLMNATP53CYP3A4 | |
| SCHEMBL9461723 | 0.81 | CYP3A4 (0.65) | APPTSHRLMNATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015898-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | GLYCOMIMETICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-4262041-A | Process for preparing a composite amphoteric ion exchange membrane | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015898-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | HBG1, HBG2, SORD | APP 4508/4885KCNH2 2668/4885TSHR 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.